Abstract
Background
Psoriatic arthritis is a chronic and debilitating condition. The biologic therapies are targeted therapeutic options that have shown promise; notably, there are substantial data supporting the use of the anti–tumor necrosis factor (TNF) agents in the treatment of psoriatic arthritis and in the prevention of radiographic progression of joint destruction. We report three cases that demonstrate the selective benefits of ustekinumab and of TNF blockers, depending on the relative severities of joint and cutaneous symptoms.
Observations
We describe three cases of psoriatic arthritis and psoriasis in patients being treated with anti-TNF agents who, after switching to ustekinumab from TNF blockers, complained of worsening joint pain, although their cutaneous findings improved. Two of these patients opted to discontinue their therapy with ustekinumab and restart anti-TNF therapy; they prioritized control of their joint pain over the skin clearing they had while taking ustekinumab.
Conclusions
Ustekinumab may not be as efficacious as agents that block TNF for the treatment of psoriatic arthritis. Further study is needed to assess its efficacy in psoriatic arthritis.
Get full access to this article
View all access options for this article.